Ruxolitinib for Symptom Control in Patients with Chronic Lymphocytic Leukaemia: a Single- Group, Phase 2 Trial

Total Page:16

File Type:pdf, Size:1020Kb

Ruxolitinib for Symptom Control in Patients with Chronic Lymphocytic Leukaemia: a Single- Group, Phase 2 Trial UC Irvine UC Irvine Previously Published Works Title Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single- group, phase 2 trial. Permalink https://escholarship.org/uc/item/1180x27h Journal The Lancet. Haematology, 4(2) ISSN 2352-3026 Authors Jain, Preetesh Keating, Michael Renner, Sarah et al. Publication Date 2017-02-01 DOI 10.1016/s2352-3026(16)30194-6 Peer reviewed eScholarship.org Powered by the California Digital Library University of California HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Lancet Haematol Manuscript Author . Author Manuscript Author manuscript; available in PMC 2018 February 01. Published in final edited form as: Lancet Haematol. 2017 February ; 4(2): e67–e74. doi:10.1016/S2352-3026(16)30194-6. Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial Preetesh Jain, M.D.,PhD1, Michael Keating, M.D.1,*, Sarah Renner, RN1, Charles Cleeland, PhD2,*, Huang Xuelin, PhD3,*, Graciela Nogueras Gonzalez, M.P.H3, David Harris, PhD1, Ping Li, PhD1, Zhiming Liu, PhD1, Ivo Veletic, PhD1, Uri Rozovski, M.D.1, Nitin Jain, M.D.1, Phillip Thompson, M.D.1, Prithviraj Bose, M.D.1, Courtney DiNardo, M.D.1, Alessandra Ferrajoli, M.D.1,*, Susan O’Brien, M.D.1,*, Jan Burger, M.D.1, William Wierda, M.D.1,*, Srdan Verstovsek, M.D.1,*, Hagop Kantarjian, M.D.1,*, and Zeev Estrov, M.D.1,* 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 2Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas Summary Background—Disease-related symptoms impair the quality of life of countless patients with chronic lymphocytic leukemia (CLL) who do not require systemic therapy. Currently available therapies are not specifically aimed at symptom control. Because stimulation of the B-cell receptor activates Janus kinase (JAK)-2 in CLL cells and the JAK2 inhibitor ruxolitinib improves symptoms of patients with myelofibrosis, we hypothesized that ruxolitinib would improve disease- related symptoms in CLL patients. Methods—Ruxolitinib (10 mg twice daily) was administered to symptomatic CLL patients who did not require systemic therapy for CLL. Scores on the brief fatigue inventory (BFI), CLL module of the MD Anderson symptom inventory (MDASI) and symptom-associated interference in daily activities (interference score; IS), were assessed prior to treatment and after 3 months of treatment. Plasma cytokine/chemokine levels were measured at baseline and at 3 months. This manuscript version is made available under the CC BY-NC-ND 4.0 license. Corresponding Author: Zeev Estrov, MD, Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030; phone: 713-794-1675; fax: 713-745-4612; [email protected]. *Authors who are full professors Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Authorship Contributions Z.E. designed the study. C.C. performed preliminary symptom score analysis and provided the symptom scores. S.R. was the study’s research nurse. P.J., U.R., C.C., S.R., and Z.E. contributed to data collection and analysis. H.X., N.G. designed the study’s statistical method and monitoring. H.X., N.G., I.V., and U.R. analyzed the data. D.H., L.P., and Z.L., performed the laboratory experiments. Z.E., M.K., N.J., P.T., P.B., C.D., A.F., S.V., S.O.B., J.B., W.W., and H.K. treated and monitored the patients. P.J. and Z.E. wrote the paper. Conflicts-of-Interest Disclosure: Z.E. receives research support from and serves as a consultant to Incyte Corporation. None of the other authors have any conflicts of interest to disclose. Jain et al. Page 2 Findings—Forty-one CLL patients (25 untreated and 16 previously treated) were enrolled. Author ManuscriptAuthor Manuscript Author Manuscript Author Manuscript Author Thirty-two (78%) of the participants experienced ≥20% reduction in the average BFI score or in the average MDASI score. 59% of the participants had ≥2 units reduction in worst fatigue score in 24 hours as assessed by the BFI. The mean percentage reductions in BFI, MDASI, and IS scores were >42% (p<0.0001). Improvements in the three symptom scores correlated with reductions in levels of IL-6, C-reactive protein, CXCL10, osteopontin, TNF-α, ICAM-1/CD54, VCAM-1/ CD106, and beta-2 microglobulin. Furthermore, treatment with ruxolitinib increased and then decreased lymphocyte counts to baseline levels or lower. Grade 3/4 cytopenias were recorded in three patients. Interpretation—In CLL patients, ruxolitinib significantly improved disease-related symptoms, reduced cytokine and chemokine levels, and increased and then decreased lymphocyte counts, likely through mobilization followed by apoptosis of CLL cells. Further studies aimed at testing the therapeutic efficacy of ruxolitinib in CLL are warranted. Funding—Supported by the Incyte Corp., MD Anderson Cancer Center Support Grant CA016672 and Award Number P01 CA049639 from the National Cancer Institute. Keywords Ruxolitinib; symptoms; fatigue; chronic lymphocytic leukemia; inflammatory cytokines/ chemokines INTRODUCTION A significant number of patients with chronic lymphocytic leukemia (CLL) who do not meet the international working group on CLL (iwCLL) 1 criteria for treatment of CLL experience fatigue and/or other disease-related debilitating symptoms that significantly impair their quality of life (QoL) and bring about severe distress and depression.2–5 Disease-associated symptoms such as fatigue, low-grade fever, night sweats, and weight loss are associated with elevated circulating levels of inflammatory cytokines and/or chemokines. Most symptomatic patients are treated with supportive care measures that provide little clinical benefit. As a consequence, a small fraction of patients with severe QoL impairment are offered systemic therapy for CLL.1. Our group has previously assessed the symptoms of 126 consecutive patients with CLL. The most severe symptoms were fatigue, disturbed sleep, drowsiness, distress, and difficulty remembering. About 70% of patients presented with a significantly abnormal symptom score. 6 Inflammatory cytokines induce disease-related symptoms7 in a variety of neoplastic diseases, 8 including hematologic malignancies such as primary myelofibrosis9,10 and CLL. 11 Elevated levels of TNF- α, IL-1β, IL-6, IL-1RA, and IFN-α were previously reported to significantly correlate with cancer associated fatigue, depression, night sweats. 12 The role of cytokines and chemokines in the initiation, maintenance, and progression of CLL has been the subject of intense research over the past two decades, 13 as elevated plasma cytokine levels10 correlate with unfavorable clinical outcome in patients with CLL. 13 Lancet Haematol. Author manuscript; available in PMC 2018 February 01. Jain et al. Page 3 We recently found that stimulation of the B-cell receptor (BCR) of CLL cells activates the Author ManuscriptAuthor Manuscript Author Manuscript Author Manuscript Author Janus kinase (JAK)-2/signal transducer and activator of transcription (STAT)-3 pathway and that the JAK1/2 inhibitor ruxolitinib inhibits the phosphorylation of JAK2 and STAT3 on tyrosine residues of these cells, inducing their apoptosis. 14 Ruxolitinib is known to reduce the levels and inhibit the effects of a number of cytokines, chemokines, and hematopoietic growth factors, providing significant clinical benefits. In patients with myelofibrosis, ruxolitinib alleviates symptoms, improves QoL, and reduces spleen size and tumor burden. 15 Similarly, ruxolitinib was found to improve symptoms and decrease inflammation biomarkers such as the acute phase reactant C-reactive protein (CRP) in patients with steroid-refractory graft-versushost disease16 or pancreatic cancer. 17 Therefore, we sought to investigate the effect of ruxolitinib on disease-related symptoms in patients with CLL. PATIENTS AND METHODS Patient enrollment and treatment This prospective, single arm, single institution, phase II clinical trial designed to test the effect of ruxolitinib on disease-related symptoms of patients with CLL was approved by The University of Texas MD Anderson Cancer Center institutional review board and supported by Incyte Corporation (clinicaltrials.gov identifier number NCT02131584). All patients in this study were enrolled between 15th September 2014 to 20th September 2015. Informed consent (verbal and written) was obtained in accordance with institutional guidelines and the Declaration of Helsinki. Patients with previously untreated or previously treated CLL that did not require therapeutic intervention according to the iwCLL guidelines1 were eligible. CLL patients with performance status ≤ 2 were eligible. According to the 2008 iwCLL guidelines, active disease should be considered if there is significant fatigue, defined as ECOG performance status 2 or worse and inability to work or perform usual activities). All participants were assessed for disease-related
Recommended publications
  • JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
    Drugs https://doi.org/10.1007/s40265-020-01261-8 CURRENT OPINION JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors Miguel Nogueira1 · Luis Puig2 · Tiago Torres1,3 © Springer Nature Switzerland AG 2020 Abstract Despite advances in the treatment of psoriasis, there is an unmet need for efective and safe oral treatments. The Janus Kinase– Signal Transducer and Activator of Transcription (JAK–STAT) pathway plays a signifcant role in intracellular signalling of cytokines of numerous cellular processes, important in both normal and pathological states of immune-mediated infamma- tory diseases. Particularly in psoriasis, where the interleukin (IL)-23/IL-17 axis is currently considered the crucial pathogenic pathway, blocking the JAK–STAT pathway with small molecules would be expected to be clinically efective. However, relative non-specifcity and low therapeutic index of the available JAK inhibitors have delayed their integration into the therapeutic armamentarium of psoriasis. Current research appears to be focused on Tyrosine kinase 2 (TYK2), the frst described member of the JAK family. Data from the Phase II trial of BMS-986165—a selective TYK2 inhibitor—in psoriasis have been published and clinical results are encouraging, with a large Phase III programme ongoing. Further, the selective TYK2 inhibitor PF-06826647 is being tested in moderate-to-severe psoriasis in a Phase II clinical trial. Brepocitinib, a potent TYK2/JAK1 inhibitor, is also being evaluated, as both oral and topical treatment. Results of studies with TYK2 inhibitors will be important in assessing the clinical efcacy and safety of these drugs and their place in the therapeutic armamentarium of psoriasis.
    [Show full text]
  • JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: a Focus on the Present and an Outlook on the Future
    biomolecules Review JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 1, 2, , 3 1,4 Jacopo Angelini y , Rossella Talotta * y , Rossana Roncato , Giulia Fornasier , Giorgia Barbiero 1, Lisa Dal Cin 1, Serena Brancati 1 and Francesco Scaglione 5 1 Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20133 Milan, Italy; [email protected] (J.A.); [email protected] (G.F.); [email protected] (G.B.); [email protected] (L.D.C.); [email protected] (S.B.) 2 Department of Clinical and Experimental Medicine, Rheumatology Unit, AOU “Gaetano Martino”, University of Messina, 98100 Messina, Italy 3 Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Pordenone, 33081 Aviano, Italy; [email protected] 4 Pharmacy Unit, IRCCS-Burlo Garofolo di Trieste, 34137 Trieste, Italy 5 Head of Clinical Pharmacology and Toxicology Unit, Grande Ospedale Metropolitano Niguarda, Department of Oncology and Onco-Hematology, Director of Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20162 Milan, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-090-2111; Fax: +39-090-293-5162 Co-first authors. y Received: 16 May 2020; Accepted: 1 July 2020; Published: 5 July 2020 Abstract: Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs.
    [Show full text]
  • Switching Between Janus Kinase Inhibitor Upadacitinib and Adalimumab Following Insufficient Response: Efficacy and Safety In
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2020-218412 on 4 November 2020. Downloaded from Rheumatoid arthritis CLINICAL SCIENCE Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis Roy M Fleischmann ,1 Ricardo Blanco ,2 Stephen Hall,3 Glen T D Thomson,4 Filip E Van den Bosch,5,6 Cristiano Zerbini,7 Louis Bessette,8,9 Jeffrey Enejosa,10 Yihan Li,10 Yanna Song,10 Ryan DeMasi,10 In- Ho Song10 Handling editor Josef S ABSTRACT Key messages Smolen Objectives To evaluate efficacy and safety of immediate switch from upadacitinib to adalimumab, or ► Additional material is What is already known about this subject? published online only. To view, vice versa, in patients with rheumatoid arthritis with non- ► In patients with rheumatoid arthritis, a treat- please visit the journal online response or incomplete- response to the initial therapy. to- target strategy is recommended, in which (http:// dx. doi. org/ 10. 1136/ Methods SELECT-COMP ARE randomised patients to therapy is optimised every 3–6 months until annrheumdis- 2020- 218412). upadacitinib 15 mg once daily (n=651), placebo (n=651) remission, or low disease activity, is achieved. or adalimumab 40 mg every other week (n=327). A For numbered affiliations see Recent treatment recommendations suggest the treat-to- target study design was implemented, with end of article. addition of a biological or targeted- synthetic blinded rescue occurring prior to week 26 for patients disease- modifying antirheumatic drug in Correspondence to who did not achieve at least 20% improvement in both patients who do not achieve treatment goals, Dr Roy M Fleischmann, The tender and swollen joint counts (’non-responders’) and and switches between mechanisms of action University of Texas at week 26 based on Clinical Disease Activity Index Southwestern Medical Center, occur commonly in clinical practice.
    [Show full text]
  • The JAK-STAT Pathway and the JAK Inhibitors
    ISSN Online: 2378-1726 Symbiosis www.symbiosisonlinepublishing.com Review Article Clinical Research in Dermatology: Open Access Open Access The JAK-STAT Pathway and the JAK Inhibitors Ana Paula Galli Sanchez1, Tatiane Ester Aidar Fernandes2, and Gustavo Martelli Palomino3 1Dermatologist and Master of Science from the Medical College of the University of São Paulo, Medical Contributor to Severe Psoriasis Clinic of the Complexo Hospitalar Padre Bento de Guarulhos, Brazil 2Dermatologist, São Paulo, Brazil 3Biologist, Master and PhD from the Program of Basic and Applied Immunology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil Received: November 17, 2020; Accepted: November 26, 2020; Published: November 30, 2020 *Corresponding author: Ana Paula Galli Sanchez, Dermatologist and Master of Science from the Medical College of the University of São Paulo, Medical Contributor to Severe Psoriasis Clinic of the Complexo Hospitalar Padre Bento de Guarulhos, Brazil. E-mail: [email protected] Abstract Dozens of cytokines that bind Type I and Type II receptors use the Janus Kinases (JAK) and the Signal Transducer and Activator of Transcription clinical(STAT) trialsproteins for skinpathway diseases. for intracellular Thus, dermatologists signaling, should orchestrating understand hematopoiesis, how the JAK-STAT inducing pathway inflammation, works as and well controlling as the mechanism the immune of action response. of the JAKCurrently, inhibitors oral whichJAK inhibitors will certainly are being become used
    [Show full text]
  • The Janus Kinase Inhibitor Ruxolitinib Prevents Terminal Shock in a Mouse Model of Arenavirus Hemorrhagic Fever
    microorganisms Communication The Janus Kinase Inhibitor Ruxolitinib Prevents Terminal Shock in a Mouse Model of Arenavirus Hemorrhagic Fever Mehmet Sahin 1, Melissa M. Remy 1 , Doron Merkler 2 and Daniel D. Pinschewer 1,* 1 Department of Biomedicine—Haus Petersplatz, Division of Experimental Virology, University of Basel, 4009 Basel, Switzerland; [email protected] (M.S.); [email protected] (M.M.R.) 2 Department of Pathology and Immunology, Division of Clinical Pathology, University Hospital of Geneva, 1211 Geneva, Switzerland; [email protected] * Correspondence: [email protected] Abstract: Arenaviruses such as Lassa virus cause arenavirus hemorrhagic fever (AVHF), but pro- tective vaccines and effective antiviral therapy remain unmet medical needs. Our prior work has revealed that inducible nitric oxide synthase (iNOS) induction by IFN-γ represents a key pathway to microvascular leak and terminal shock in AVHF. Here we hypothesized that Ruxolitinib, an FDA- approved JAK inhibitor known to prevent IFN-γ signaling, could be repurposed for host-directed therapy in AVHF. We tested the efficacy of Ruxolitinib in MHC-humanized (HHD) mice, which develop Lassa fever-like disease upon infection with the monkey-pathogenic lymphocytic chori- omeningitis virus strain WE. Anti-TNF antibody therapy was tested as an alternative strategy owing to its expected effect on macrophage activation. Ruxolitinib but not anti-TNF antibody prevented hypothermia and terminal disease as well as pleural effusions and skin edema, which served as readouts of microvascular leak. As expected, neither treatment influenced viral loads. Intrigu- Citation: Sahin, M.; Remy, M.M.; ingly, however, and despite its potent disease-modifying activity, Ruxolitinib did not measurably Merkler, D.; Pinschewer, D.D.
    [Show full text]
  • Cytokine Storm Release Syndrome and the Prospects for Immunotherapy with COVID-19, Part 4: the Role of JAK Inhibition Posted August 27, 2020
    COVID-19 CURBSIDE CONSULTS Leonard H. Calabrese, DO Tiphaine Lenfant, MD Cassandra Calabrese, DO Department of Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute, Orthopedic & Rheumatologic Institute Department Orthopedic & Rheumatologic Institute, and Cleveland Clinic of Infectious Disease, Cleveland Clinic; Assistance Department of Infectious Disease, Cleveland Clinic Publique des Hôpitaux de Paris, Université de Paris; Hôpital européen Georges Pompidou, Service de médecine interne, Paris, France Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition Posted August 27, 2020 ■ ABSTRACT This review focuses on an alternative strategy, ie, This review focuses an alternative strategy utilizing small targeted synthetic therapies, utilizing small molecules molecules to inhibit a key signal-transduction pathway, to inhibit a key shared signal-transduction pathway, the Janus kinase-signal transducer and activator of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. The JAK-STAT transcription (JAK-STAT) signaling pathway. The pathway mediates biologic activity for a large number of JAK-STAT pathway mediates biologic activity for a inflammatory cytokines and mediators. large number of inflammatory cytokines and media- tors and has been targeted by several therapeutics, ■ INTRODUCTION which are now in clinical use across
    [Show full text]
  • Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes In
    medRxiv preprint doi: https://doi.org/10.1101/2020.08.10.20172189; this version posted August 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis Lucas Walz1,2, Avi J. Cohen2, Andre P. Rebaza, MD3, James Vanchieri2, Martin D. Slade, MPH4, Charles S. Dela Cruz, MD, PhD2,5*, Lokesh Sharma, PhD2* 1 Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, 06520, USA 2 Section of Pulmonary and Critical Care and Sleep Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA 3 Section of Pediatric Pulmonary, Allergy, Immunology and Sleep Medicine, Dept of Pediatrics, Yale School of Medicine, New Haven, CT, 06520, USA 4 Department of Internal Medicine, Yale School of Medicine, New Haven, CT, 06520, USA. 5 Department of Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, 06520, USA. Corresponding Authors: Lokesh Sharma, PhD, Instructor in Medicine, Department of Internal Medicine, Section of Pulmonary and Critical Care and Sleep Medicine, Yale University School of Medicine, S440, 300 Cedar Street, New Haven, CT 06520; e-mail: [email protected] Charles S. Dela Cruz, MD, PhD, Associate Professor of Medicine, Department of Internal Medicine, Section of Pulmonary and Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT 06520; e-mail: [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • 1 Clinical Significance of Janus Kinase Inhibitor Selectivity
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Online Research @ Cardiff Clinical Significance of Janus Kinase Inhibitor Selectivity Professor Ernest H Choy Head of Rheumatology and Translational Research Division of Infection and Immunity Director of Arthritis Research UK and Health and Care Research Wales CREATE Centre Correspondence to: Professor Ernest Choy, CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University School of Medicine, Tenovus Building, Heath Park, Cardiff, Wales, United Kingdom CF14 4XN. Email: [email protected] Key words: rheumatoid arthritis, Janus Kinase, treatment, targeted synthetic DMARDs, DMARDs Acknowledgement: The CREATE Centre was funded by Arthritis Research UK and Health and Care Research Wales. Statement: This manuscript has no funding supporting. Key messages: 1. JAKi selectively is relative and not absolute. 2. Current approved JAKi and those in development significantly inhibit JAK1 isoform. 3. JAK1 is an effective target in RA although zoster reactivation is a class effect. 1 Abstract Cytokines are key drivers of inflammation in rheumatoid arthritis (RA). Anti-cytokine therapy has improved the outcome of RA. Janus kinases (JAK) are intracellular tyrosine kinases linked to intracellular domains of many cytokine receptors. There are four JAK isoforms: JAK1, JAK2, JAK3 and TYK2. Different cytokine receptor families utilise specific JAK isoforms for signal transduction. Phosphorylation of JAK when cytokine binds to its cognate receptor leads to phosphorylation of other intracellular molecules that eventually leads to gene transcription. Oral JAK inhibitors have been developed as anti-cytokine therapy in RA. Two JAK inhibitors, tofacitinib and baricitinib. have been approved recently for the treatment of RA.
    [Show full text]
  • Standards, Perspektiven Und Grenzen Der Konservativen Therapie
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2013 Review: new anti-cytokines for IBD: what is in the pipeline? Scharl, Michael ; Vavricka, Stephan R ; Rogler, Gerhard Abstract: Significant advances have been achieved in the understanding of the pathogenesis ofinflam- matory bowel disease (IBD). A number of susceptibility genes have been detected by large genome wide screening-approaches. New therapeutic concepts emerge from these insights. The most important progress in recent years certainly is the introduction of biologics in the therapy of IBD. TNF blockers have been shown to be very effective for the control of complicated disease courses. Currently, in addition to the three already established anti-TNF antibodies, new anti-TNF molecules, for example Golimumab, are in clinical trials and also reveal promising results. However, not all of the patients respond to anti- TNF treatment and many patients lose their response. Therefore, additional therapeutic approaches are urgently needed. Attractive therapy targets are cytokines as well as their receptors and signaling pathways. At the moment a large number of biologicals and inhibitors are tested in clinical trials and some of them provide very promising results for the treatment of IBD patients. In particular, inhibition of IL-12p40 by specific antibodies as well as of the janus kinase (JAK)3 by a small molecule promiseto be very effective approaches. Though antibodies targeting for example IL-6, IL-6R, IL-13 orCCR9are only in the early steps of clinical development, they have already demonstrated to be a possible treatment option which needs to be confirmed in further trials.
    [Show full text]
  • JPET#223784 Original Article Title: Topically Administered Janus
    JPET Fast Forward. Published on July 9, 2015 as DOI: 10.1124/jpet.115.223784 This article has not been copyedited and formatted. The final version may differ from this version. JPET#223784 Original Article Title: Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Anti-Pruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis Tomoki Fukuyama, Sarah Ehling, Elizabeth Cook and Wolfgang Bäumer Downloaded from Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina jpet.aspetjournals.org State University, North Carolina, USA at ASPET Journals on September 25, 2021 JPET Fast Forward. Published on July 9, 2015 as DOI: 10.1124/jpet.115.223784 This article has not been copyedited and formatted. The final version may differ from this version. JPET#223784 Running Title: Availability of JAK-inhibitors on Allergic Dermatitis Address correspondence to: Dr. Wolfgang Bäumer, Associate Professor of Pharmacology Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Drive, Raleigh, North Carolina 27607, USA., Tel.: 1+ 919 513 1885., Fax.: 1+ 919 513 3044. E-mail addresses: [email protected] Downloaded from Number of text pages: 38 pages Number of tables: 3 tables Number of figure: 7 figures Number of text references: 44 references jpet.aspetjournals.org Number of words in the Abstract: 244 words Number of words in the Introduction: 605 words Number of words in the Discussion: 1500
    [Show full text]
  • Pathogenesis of Crohnps Disease
    Published: 02 April 2015 © 2015 Faculty of 1000 Ltd Pathogenesis of Crohn’s disease Ray Boyapati1,2, Jack Satsangi1,2 and Gwo-Tzer Ho*1,2 Addresses: 1Centre for Inflammation Research, Queens Medical Research Institute, University of Edinburgh, Edinburgh, EH16 4TJ, UK; 2Gastrointestinal Unit, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, EH4 2XU, UK * Corresponding author: Gwo-Tzer Ho ([email protected]) F1000Prime Reports 2015, 7:44 (doi:10.12703/P7-44) All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/b/7/44 Abstract Significant progress in our understanding of Crohn’s disease (CD), an archetypal common, complex disease, has now been achieved. Our ability to interrogate the deep complexities of the biological processes involved in maintaining gut mucosal homeostasis is a major over-riding factor underpinning this rapid progress. Key studies now offer many novel and expansive insights into the interacting roles of genetic susceptibility, immune function, and the gut microbiota in CD. Here, we provide overviews of these recent advances and new mechanistic themes, and address the challenges and prospects for translation from concept to clinic. “I am on the edge of mysteries and the veil is getting thinner effective in only approximately 50% [5], there remains a and thinner.” significant unmet need for novel therapeutics to prevent, Louis Pasteur alter the natural history of, and ultimately cure CD.
    [Show full text]
  • The Novel JAK Inhibitor CYT387 Suppresses Multiple Signalling Pathways, Prevents Proliferation and Induces Apoptosis in Phenotypically Diverse Myeloma Cells
    Leukemia (2011) 25, 1891–1899 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells KA Monaghan1,2, T Khong1,2, CJ Burns3 and A Spencer1,2 1Myeloma Research Group, Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; 2Australian Centre for Blood Diseases, Department of Clinical Haematology, Monash University, Melbourne, Victoria, Australia and 3YM BioSciences Australia, Melbourne, Victoria, Australia Janus kinases (JAKs) are involved in various signalling MM. Some human myeloma cell lines (HMCL) cannot pathways exploited by malignant cells. In multiple myeloma proliferate or survive without exogenous IL-6,9,10 and some (MM), the interleukin-6/JAK/signal transducers and activators of conventional drugs are ineffective in the presence of IL-6.11–13 transcription (IL-6/JAK/STAT) pathway has been the focus of The bone marrow microenvironment, known to provide research for a number of years and IL-6 has an established role 14 in MM drug resistance. JAKs therefore make a rational drug supportive signals to MM cells, produces IL-6; hence, target for anti-MM therapy. CYT387 is a novel, orally bioavail- reducing the pro-survival effect of IL-6 may abrogate the drug- able JAK1/2 inhibitor, which has recently been described. This resistant phenotype of MM. CD45 is a phenotypic marker preclinical evaluation of CYT387 for treatment of MM demon- expressed by some myeloma cells, which has been reported to strated that CYT387 was able to prevent IL-6-induced phos- influence IL-6 responsiveness.15 It is therefore likely that CD45 phorylation of STAT3 and greatly decrease IL-6- and insulin-like growth factor-1-induced phosphorylation of AKT and extra- expression might affect sensitivity to JAK inhibitors.
    [Show full text]